Cargando…

A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-Containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy

Background and Objective: Little is known about the anti-pigmentation effects of whitening agents on solar lentigines. Epidermal growth factor (EGF) has been used as a booster for wound healing in the skin, and it has been suggested to have anti-pigmentation effects. This study aimed to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hye One, Kim, Hye Ran, Kim, Jin Cheol, Kang, Seok Young, Jung, Min Je, Chang, Sung Eun, Park, Chun Wook, Chung, Bo Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918714/
https://www.ncbi.nlm.nih.gov/pubmed/33668564
http://dx.doi.org/10.3390/medicina57020166
_version_ 1783657987191078912
author Kim, Hye One
Kim, Hye Ran
Kim, Jin Cheol
Kang, Seok Young
Jung, Min Je
Chang, Sung Eun
Park, Chun Wook
Chung, Bo Young
author_facet Kim, Hye One
Kim, Hye Ran
Kim, Jin Cheol
Kang, Seok Young
Jung, Min Je
Chang, Sung Eun
Park, Chun Wook
Chung, Bo Young
author_sort Kim, Hye One
collection PubMed
description Background and Objective: Little is known about the anti-pigmentation effects of whitening agents on solar lentigines. Epidermal growth factor (EGF) has been used as a booster for wound healing in the skin, and it has been suggested to have anti-pigmentation effects. This study aimed to evaluate the effect and safety of EGF-containing ointment for treating solar lentigines with a Q-switched (QS) 532 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (Bluecore company, Seoul, Republic of Korea). Materials and Methods: Subjects who underwent QS 532 nm Nd:YAG laser treatment of solar lentigines were randomly assigned to treatment with an EGF ointment or petrolatum. After the laser procedure, the subjects were administered the test ointment twice a day for 4 weeks. The physician’s assessment of the degree of pigment clearance and patient’s satisfaction were assessed after 4 and 8 weeks. Additionally, the melanin index (MI), erythema index (EI), transepidermal water loss (TEWL), and post-inflammatory hyperpigmentation (PIH) were evaluated. This trial was registered with ClinicalTrials.gov (NCT04704245). Results: The blinded physician’s assessment using 5-grade percentage improvement scale and patient’s satisfaction were significantly higher in the study group than in the control group at the 4th and 8th weeks. The MI was significantly higher in the control group than in the study group at the 4th and 8th weeks. The EI and TEWL did not differ significantly between the two groups at either time point. The incidence of PIH was higher in the control group (37.5%) than in the EGF group (7.14%) at the 8th week. Conclusions: The application of EGF-containing ointment on facial solar lentigines with a QS 532 nm Nd:YAG laser showed efficient and safe therapeutic effects, with less PIH. Thus, EGF-containing ointment could be suggested as the promising adjuvant treatment strategy with a QS laser for solar lentigines.
format Online
Article
Text
id pubmed-7918714
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79187142021-03-02 A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-Containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy Kim, Hye One Kim, Hye Ran Kim, Jin Cheol Kang, Seok Young Jung, Min Je Chang, Sung Eun Park, Chun Wook Chung, Bo Young Medicina (Kaunas) Article Background and Objective: Little is known about the anti-pigmentation effects of whitening agents on solar lentigines. Epidermal growth factor (EGF) has been used as a booster for wound healing in the skin, and it has been suggested to have anti-pigmentation effects. This study aimed to evaluate the effect and safety of EGF-containing ointment for treating solar lentigines with a Q-switched (QS) 532 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (Bluecore company, Seoul, Republic of Korea). Materials and Methods: Subjects who underwent QS 532 nm Nd:YAG laser treatment of solar lentigines were randomly assigned to treatment with an EGF ointment or petrolatum. After the laser procedure, the subjects were administered the test ointment twice a day for 4 weeks. The physician’s assessment of the degree of pigment clearance and patient’s satisfaction were assessed after 4 and 8 weeks. Additionally, the melanin index (MI), erythema index (EI), transepidermal water loss (TEWL), and post-inflammatory hyperpigmentation (PIH) were evaluated. This trial was registered with ClinicalTrials.gov (NCT04704245). Results: The blinded physician’s assessment using 5-grade percentage improvement scale and patient’s satisfaction were significantly higher in the study group than in the control group at the 4th and 8th weeks. The MI was significantly higher in the control group than in the study group at the 4th and 8th weeks. The EI and TEWL did not differ significantly between the two groups at either time point. The incidence of PIH was higher in the control group (37.5%) than in the EGF group (7.14%) at the 8th week. Conclusions: The application of EGF-containing ointment on facial solar lentigines with a QS 532 nm Nd:YAG laser showed efficient and safe therapeutic effects, with less PIH. Thus, EGF-containing ointment could be suggested as the promising adjuvant treatment strategy with a QS laser for solar lentigines. MDPI 2021-02-13 /pmc/articles/PMC7918714/ /pubmed/33668564 http://dx.doi.org/10.3390/medicina57020166 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Hye One
Kim, Hye Ran
Kim, Jin Cheol
Kang, Seok Young
Jung, Min Je
Chang, Sung Eun
Park, Chun Wook
Chung, Bo Young
A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-Containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy
title A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-Containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy
title_full A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-Containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy
title_fullStr A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-Containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy
title_full_unstemmed A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-Containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy
title_short A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-Containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy
title_sort randomized controlled trial on the effectiveness of epidermal growth factor-containing ointment on the treatment of solar lentigines as adjuvant therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918714/
https://www.ncbi.nlm.nih.gov/pubmed/33668564
http://dx.doi.org/10.3390/medicina57020166
work_keys_str_mv AT kimhyeone arandomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT kimhyeran arandomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT kimjincheol arandomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT kangseokyoung arandomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT jungminje arandomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT changsungeun arandomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT parkchunwook arandomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT chungboyoung arandomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT kimhyeone randomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT kimhyeran randomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT kimjincheol randomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT kangseokyoung randomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT jungminje randomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT changsungeun randomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT parkchunwook randomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy
AT chungboyoung randomizedcontrolledtrialontheeffectivenessofepidermalgrowthfactorcontainingointmentonthetreatmentofsolarlentiginesasadjuvanttherapy